Business · 07/09/2023Updated: 10/17/2026 · 1 min read
FDA Announces Public Advisory Committee Meeting on Sickle Cell Disease Treatment
Summary
The FDA is hosting a public meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee to discuss a biologics license application for a potential treatment of sickle cell disease in patients 12 years and older.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →